Navigation Links
Targeted investigational therapy potential to overcome crizotinib resistance in lung cancers
Date:10/20/2013

BOSTON PF-06463922, an investigational drug being developed by Pfizer Inc., has the potential to become a new treatment option for patients who have lung cancer harboring abnormalities in the ALK gene, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

About 3 to 5 percent of lung cancers harbor ALK gene abnormalities. The drug crizotinib (Xalkori), which blocks ALK protein kinase activity, was approved in August 2011 by the U.S. Food and Drug Administration for the treatment of patients who have these lung cancers. Although robust responses to crizotinib are observed for lung cancers harboring ALK gene abnormalities, the majority eventually become resistant to the effects of the drug. In many cases, resistance arises because of genetic mutations in ALK.

"Resistance to targeted therapies such as crizotinib is a major challenge when treating patients with cancer," said Tod Smeal, Ph.D., associate research fellow in the Oncology Research Unit at Pfizer Inc. in San Diego, Calif. "Our goal is to take advantage of everything we have learned about designing drugs that target kinases like ALK and the ways in which lung cancers become resistant to crizotinib to develop the best next-generation ALK inhibitor we can.

"Our preclinical studies suggest that we are making progress toward achieving our goal: PF-06463922 has potent ALK-inhibiting activity, it is capable of inhibiting all the crizotinib-resistant ALK mutants so far detected in patients, and it can efficiently access the brain. We are excited about these preclinical results and very hopeful that they will translate into meaningful responses in the clinic."

After carefully designing PF-06463922, Smeal and colleagues first showed in cell assays that it potently inhibited the activity of ALK and all eight of the mutant forms of ALK known to cause resistance to crizotinib
'/>"/>

Contact: Lauren Riley
lauren.riley@aacr.org
215-446-7155
American Association for Cancer Research
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Targeted therapeutics for colon cancer to be presented at AACR meeting
2. First targeted nanomedicine to enter human clinical studies
3. Highly targeted irradiation as good as whole breast radiotherapy in early stage cancer
4. Dana-Farber: Study reports first success of targeted therapy in type of non-small cell lung cancer
5. Inflammatory pathway spurs cancer stem cells to resist HER2-targeted breast cancer treatment
6. Killer infections targeted by hospital study
7. Lower risk of serious side-effects in trials of new targeted drugs
8. Treating drug resistant cancer through targeted inhibition of sphingosine kinase
9. Pitt: Targeted oxidation-blocker prevents secondary damage after traumatic brain injury
10. Deadly witch hunts targeted by grassroots womens groups
11. Large lung cancer study shows potential for more targeted therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2014)... more than 15 years ago, the PTEN gene has ... the onset and progression of numerous cancers. Consequently, when ... grow unchecked and cancer can develop. , Now a ... Center (BIDMC) helps explain more precisely how PTEN exerts ... can set cells on a cancerous course. The new ...
(Date:4/24/2014)... Benefits often coexist with the negative and stressful outcomes ... later diagnosed with a life-limiting illness, says a recent ... Waterloo. , While the challenges are numerous and life-changing ... who participated in the Waterloo-led research reported positive outcomes ... findings appear in the most recent issue of the ...
(Date:4/24/2014)... the Center for BrainHealth will bring together national ... brain-related challenges at its inaugural Brain Health Summit, ... Featured speakers will include Dr. Sandra Bond Chapman, ... BrainHealth, U.S. Senator Chuck Grassley (R-IA), U.S. Representative ... Secretary for Policy and Early Learning, U.S. Department ...
(Date:4/24/2014)... of prescription opioid overdose deaths was outlined yesterday in ... leaders of agencies in the U.S. Department of Health ... care providers to expand their use of medications to ... a number of misperceptions that have limited access to ... medications can be used in combination with behavior therapies ...
(Date:4/24/2014)... one of 30 grants from the National Cancer Institute ... in its new National Clinical Trials Network ... investigators charged with distributing resources in a more effective ... reflects recommendations from a 2010 Institute of Medicine ... Faster design, launch, and completion of clinical ...
Breaking Medicine News(10 mins):Health News:Surprising new insights into the PTEN tumor suppressor gene 2Health News:Surprising new insights into the PTEN tumor suppressor gene 3Health News:Parents of severely ill children see benefits as caregivers, says study 2Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 3Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 4Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3
... of the new health reform in China have been ... one of the most important policies ,The National Essential ... solve the high cost of drugs in China through ... drug prices that cover a wide range of diseases ...
... Million Contribution Mark to Support Families Living with Autism and Other ... ... -- Safeway (NYSE:SWY) captures Easter Seals, highest ... for children and adults with autism and other disabilities in 2009 ...
... celebrating their 50th year anniversary this month. Founded in 1959, ... various industries. In the 1970s, Key Instruments began focusing exclusively ... flow meters, and then expanded to include molded flow meters, ... ...
... tattoo to fit horizontal tummy tuck and c-section scars. It is made ... was designed to last 1-3 days. It can be applied and removed ... ... ScarArt, an innovative new company specializing in adhesive products used to conceal ...
... provide affordable and timely transcription services , ... ... Inc., the nation,s leading provider of transcription services to group ... will incorporate M*Modal,s Conversational Documentation Services (CDS) ...
... NuSil Technology announced a definitive agreement to acquire the pharmaceutical ... ... Carpinteria, Calif. (Vocus) May 21, 2009 -- NuSil ... silicone compounds for the healthcare and pharmaceutical industries, announced a ...
Cached Medicine News:Health News:Frost & Sullivan Looks at the Influence of China's New Health Reform on the Pharmaceutical Market 2Health News:Frost & Sullivan Looks at the Influence of China's New Health Reform on the Pharmaceutical Market 3Health News:Safeway Earns Easter Seals' All-Time Top Corporate Partner Designation 2Health News:Safeway Earns Easter Seals' All-Time Top Corporate Partner Designation 3Health News:Safeway Earns Easter Seals' All-Time Top Corporate Partner Designation 4Health News:Key Instruments Celebrates 50 Year Anniversary 2Health News:Key Instruments Celebrates 50 Year Anniversary 3Health News:ScarArt -Creatively Camouflage Abdominal Scars 2Health News:MxSecure Expands Offerings with M*Modal Speech Recognition Solution 2Health News:MxSecure Expands Offerings with M*Modal Speech Recognition Solution 3Health News:NuSil Technology Acquires Pharmaceutical Antifoam (Simethicone) Business from Bluestar Silicones 2Health News:NuSil Technology Acquires Pharmaceutical Antifoam (Simethicone) Business from Bluestar Silicones 3
(Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
(Date:1/15/2014)... 15, 2014 Shire plc (LSE: SHP, NASDAQ: ... Fair Trading (OFT) approval condition to the announced tender offer for ... As a result of the waiver, the transaction is ... the tender offer on January 24, 2014 following the currently scheduled ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2
... 26, 2011 Masimo (NASDAQ: MASI ) today ... Goldman Sachs 32nd Annual Global Healthcare Conference at Terranea in ... 8:40 a.m. Pacific Time.  A live audiocast of the presentation ... .  A replay of the audiocast will be available following ...
... OTC Markets Group Inc. (OTCQX: OTCM), ... the world,s largest electronic marketplace for broker-dealers to trade ... (TSX.V: VRS; OTCQX: VRSEF), a medical device company ... of cancer, is now trading on the OTC market,s ...
Cached Medicine Technology:Masimo to Present at Goldman Sachs 32nd Annual Global Healthcare Conference 2Verisante Technology Inc. Joins OTCQX 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: